Smith Michael David 4
4 · KalVista Pharmaceuticals, Inc. · Filed Dec 18, 2020
Insider Transaction Report
Form 4
Smith Michael David
Sr. VP, Development
Transactions
- Award
Stock Option (right to buy)
2020-12-16+25,000→ 25,000 totalExercise: $10.20Exp: 2030-06-16→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]Represents performance stock options granted to the Reporting Person on June 16, 2020. As a result of the Reporting Person having met the applicable performance criteria, 1/48 of the total stock options vests monthly over a 4-year period commencing on December 16, 2020 until fully vested, subject to the Reporting Person's continued service through each vesting date.